Acute Myeloid Leukemia Archives - Cancer Therapy Advisor

Monitoring patient status in the infusion room.

Sorafenib Maintenance Therapy After Allo-HSCT Improves Outcomes in FLT3-ITD–Positive AML

By

July 30, 2020

Among patients with FLT3-internal tandem repeats, sorafenib maintenance therapy reduces the risk of relapse and death after allo-HSCT.

Patients who receive chemotherapy or radiation therapy are at risk for developing oral mucositis, wh

Hematologic Cancers

Dental Screenings Prior to Induction Chemotherapy for Acute Myeloid Leukemia

By

Vicki Moore, PhD

July 24, 2020

Researchers found that identifying and treating acute odontogenic disease before induction chemotherapy prevented infectious dental emergencies in AML patients.

Median overall survival was 42 months in patients who received sorafenib and 13 months in patients who received chemotherapy alone.

General Oncology

A Missed Opportunity in Expanded Access Limits Real-World Insights

By

Christina Bennett, MS

July 7, 2020

An expanded access protocol for gemtuzumab ozogamicin gathered only safety data, no efficacy data, limiting insights into real-world use.

ROPETAR failed to demonstrate any clinical benefit in alternating treatment with pazopanib and evero

Hematologic Cancers

Treating Strategies for Patients With Relapsed/Refractory Acute Myeloid Leukemia

By

Tori Rodriguez, MA, LPC

July 1, 2020

Although numerous clinical studies have aimed to treat AML, most results ⁠have been disappointing, according to authors of a publication in Blood.

EHA25 Virtual Congress

Addition of Venetoclax to Azacitidine Associated With Clinically Significant OS Benefit in AML

By

Susan Moench, PhD, PA-C

June 17, 2020

The addition of venetoclax to azacitidine was associated with a 34% reduction in risk of death.

Nilotinib in combination with chemotherapy is highly effective in Philadelphia chromosome-, BCR-ALB1

EHA25 Virtual Congress

FLT3-ITD With an Insertion Site in the Beta1-Sheet Prognostic for Poor Outcomes in AML

By

Andrea S. Blevins Primeau, PhD, MBA

June 15, 2020

Among adult patients with newly diagnosed AML, the presence of an FLT3-ITD mutation with an insertion site in the beta1-sheet was associated shorter survival.

Immune checkpoint inhibitors may be effective for treating elderly patients with melanoma without dr

EHA25 Virtual Congress

Real World Evidence Shows OS Improvements in Older Patients With AML From 2000 to 2016

By

Susan Moench, PhD, PA-C

June 13, 2020

A population-based study included nearly 4000 patients diagnosed with AML from 2000 to 2016 in Denmark.

Peripheral blood sample MRD assessment will likely come into routine clinical use in the next few years, according to an expert who specializes in CLL.

EHA25 Virtual Congress

Venetoclax Plus Low-Dose Cytarabine Improved OS in Untreated AML Ineligible for Intense Chemotherapy

By

Andrea S. Blevins Primeau, PhD, MBA

June 12, 2020

In an updated analysis, venetoclax plus low-dose cytarabine improved OS compared with placebo among patients with untreated AML who were ineligible for intense chemotherapy.

Hematologic Cancers

KIR Alloreactivity, Genotype in Unrelated Donor Selection Not Significant to Pediatric AML, ALL Outcomes

By

Jonathan Goodman, MPhil

April 23, 2020

Unrelated donor selection should not be based on KIR in any of the evaluated settings, study results suggest.

Hematologic Cancers

Features, Outcomes in Therapy-Related vs De Novo Acute Myeloid Leukemia

By

Vicki Moore, PhD

April 20, 2020

Clinicopathologic and genetic characteristics of therapy-related and de novo core-binding factor AML were studied in a multicenter, retrospective analysis.